Abstracts tagged "Amyopathic dermatomyositis"

Abstract Number: 120 • 2020 Pediatric Rheumatology Symposium
Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years
Jessica Neely¹, Adam Huber ² and Susan Kim ³ for the CARRA investigators, ¹University of California, San Francisco, San Francisco, California, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³University of California, San Francisco, San Francisco
Background/Purpose: The New CARRA Registry of Juvenile Myositis (JM) was developed in 2017 to collect 10-year longitudinal data to increase knowledge of the course of…
Abstract Number: 410 • 2019 ACR/ARP Annual Meeting
Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review
Taiga Kuga¹, Yoshiyuki Abe ², Kurisu Tada ³, Masakazu Matsushita ¹, Ken Yamaji ¹ and Naoto Tamura ¹, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, Juntendo University, Tokyo, Japan, Tokyo, Japan, ³Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Anti-aminoacyl-tRNA synthetase antibodies (anti-ARS antibodies) are related to Idiopathic Inflammatory Myopathy (IIM) and Anti-Synthetase Syndrome (ASS). While anti-TIF1-γ antibody and anti-NXP-2 antibody are highly…
Abstract Number: 2128 • 2019 ACR/ARP Annual Meeting
Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality
Dipekka Soni¹, David Maniscalco ², Srihari Veeraraghavan ³, Justin Cheeley ³ and Arezou Khosroshahi ¹, ¹Emory University, Atlanta, GA, ²Emory University, Altanta, ³Emory University, Atlanta
Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung…
Abstract Number: 2843 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Victoria Werth¹, David Pearson ², Joyce Okawa ², Rui Feng ³, Josef Concha ², Basil Patel ², Emily Hejazi ², Scott Constantine ⁴, Nancy Dgetluck ⁴ and Barbara White ⁴, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Philadelphia Veteran Affairs Medical Center, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Lenabasum is a rationally-designed preferential cannabinoid receptor type 2 agonist that activates resolution of innate immune responses to reduce tissue inflammation and fibrotic processes.…
Abstract Number: 405 • 2019 ACR/ARP Annual Meeting
Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature
Mohammad Ryadh Pokeerbux¹, Luc Dauchet ², Benjamin Lopez ³, Hélène Maillard ¹, Sandrine Morell-Dubois ¹, Eric Auxenfants ⁴ and Eric Hachulla ⁵, ¹Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ²Department of Epidemiology, CHU Lille, University of Lille, Lille, France, ³Institute of Immunology, CHU Lille, University of Lille, Lille, France, ⁴Department of Internal Medicine, Roubaix Hospital, Roubaix, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: Anti-MDA5 dermatomyositis is characterized by little or no muscle involvement, distinct cutaneous features and an increased risk of severe interstitial lung disease (ILD) with…
Abstract Number: 2284 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001
Victoria P. Werth^1,2, David Pearson^1,2, Joyce Okawa^1,2, Rui Feng³, Josef Concha^1,2, Basil Patel^1,2, Emily Hejazi^1,2, Caitlin Cornwall⁴, Scott Constantine⁴ and Barbara White⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³University of Pennsylvania, Philadelphia', PA, ⁴Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability…
Abstract Number: 2298 • 2018 ACR/ARHP Annual Meeting
Developing a Classification Criteria for Cutaneous Dermatomyositis Utilizing the Delphi Technique
Josef Concha¹, Victoria P. Werth¹, Joseph F. Merola², David Fiorentino³, Jan Dutz⁴, Manabu Fujimoto⁵, Mark Goodfield⁶, Chia-Chun Ang⁷, Filippa Nyberg⁸ and Beatrix Volc-Platzer⁹, ¹University of Pennsylvania, Philadelphia, PA, ²Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Dermatology, Stanford University School of Medicine, Stanford, CA, ⁴Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ⁵University of Tsukuba, Faculty of Medicine, Department of Dermatology, Tsukuba, Japan, ⁶Leeds General Infirmary, Leeds, United Kingdom, ⁷Changi General Hospital, Singapore, Singapore, ⁸Karolinska Institute, Solna, Sweden, ⁹Wiener Krankenanstaltenverbund, Vienna, Austria
Background/Purpose: The new European League Against Rheumatism / American College of Rheumatology (EULAR / ACR) classification criteria for inflammatory myopathies are able to identify patients…
Abstract Number: 2977 • 2018 ACR/ARHP Annual Meeting
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
Nithin Reddy^1,2, Majid Zeidi^1,2, Barbara White³ and Victoria P. Werth^1,2, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 (CB2) agonist that activates resolution of innate immune responses. CB2 is a G-protein coupled…
Abstract Number: 7L • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis
Victoria P. Werth¹, Emily Hejazi², Sandra M. Pena¹, Jessica S. Haber³, Joyce Okawa¹, Rui Feng⁴, Kirubel Gabre², Josef Concha², Caitlin Cornwall⁵, Nancy Dgetluck⁶, Scott Constantine⁵ and Barbara White⁵, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Corbus Pharmaceuticals, Inc., Norwood, MA, ⁶Biostatistics, Corbus Pharmaceuticals, Inc., Norwood, MA

Background/Purpose: Effective treatment options are limited for refractory skin disease in dermatomyositis (DM). Anabasum is a non-immunosuppressive, synthetic, oral preferential CB2 agonist that triggers resolution…
Abstract Number: 2156 • 2017 ACR/ARHP Annual Meeting
Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist
Victoria P Werth¹, Emily Hejazi², Sandra M. Pena³, Jessica S. Haber⁴, Joyce Okawa³, Rui Feng⁵, Kirubel Gabre², Josef Concha², Scott Constantine⁶ and Barbara White⁶, ¹University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁵Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁶Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: There are limited treatment options and no published double-blind randomized placebo-controlled trials for the treatment of skin manifestations of dermatomyositis (DM). There is no…
Abstract Number: 2160 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Anti-Aminoacyl tRNA Synthetase Antibodies Which Are Positive By ELISA but Not By Immunoprecipitation – the Variations of Antigen Recognition and the Association with Interstitial Lung Diseases but Not Myositis –
Yuki Ishikawa^1,2, Ran Nakashima¹, Takaki Nojima^3,4, Takuya Isayama⁵, Nobuo Kuramoto¹, Kosaku Murakami¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Clinical Immunology and Rheumatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ³Clinical Immunology and Rheumatolog, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Nojima Internal Medicine Clinic, Hiroshima, Japan, ⁵Medical & Biological Laboratories CO.,LTD., Nagoya, Japan
Background/Purpose: Anti-aminoacyl tRNA synthetase (ARS) antibodies are associated with common clinical characters, which are fever, polyarthritis, interstitial lung disease (ILD), Raynaud’s phenomenon, mechanic’s hand and…
Abstract Number: 2163 • 2017 ACR/ARHP Annual Meeting
Clinical Utilization Patterns and Performance of Commercial Myositis Autoantibody Panels in Routine Practice
Prateek C. Gandiga*¹, Junqian Zhang*², Preethi Thomas¹, Victoria P. Werth^2,3, Sapna Sangani¹, Sharon L. Kolasinski¹ and Michael D. George¹, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Myositis autoantibody testing is now widely commercially available, with an evolving role in routine clinical care. However, the use and performance of commercial "myositis…
Abstract Number: 1368 • 2016 ACR/ARHP Annual Meeting
Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease
Edward J. Oberle^1,2, Dominic O. Co^3,4, Yvonne Chiu^3,4, Michelle Bayer^4,5, Adam Huber⁶, Hatice Ezgi Baris⁷ and Susan Kim⁸, ¹Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Pediatrics, Ohio State University, Columbus, OH, ³Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁴Children's Hospital of Wisconsin, Milwaukee, WI, ⁵Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁶Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁷Boston Children's Hospital, Boston, MA, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of the skin and striated muscle. A subset of patients can present with rash only, labeled…
Abstract Number: 1369 • 2016 ACR/ARHP Annual Meeting
Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Takayuki Kishi², Nastaran Bayat², Ira N. Targoff³, Lan Wu², Olcay Y. Jones^1,4, Rodolfo Curiel¹, Frederick W. Miller² and Lisa G. Rider^1,2, ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ³University of Oklahoma, Oklahoma City, OK, ⁴Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Clinically Amyopathic Juvenile Dermatomyositis (CAJDM) is a distinct clinical phenotype of JDM in which patients (pts) often have characteristic JDM rashes with little…
Abstract Number: 2307 • 2016 ACR/ARHP Annual Meeting
Influence of Season and Residential Environment on Development of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis with Interstitial Lung Disease
Naoshi Nishina¹, Shinji Sato², Yasushi Kawaguchi³, Atsushi Kawakami⁴, Maasa Tamura⁵, Kei Ikeda⁶, Takahiro Nunokawa⁷, Yoshinori Tanino⁸, Katsuaki Asakawa⁹, Yuko Kaneko¹⁰, Takahisa Gono¹¹, Kenichi Masui¹², Masataka Kuwana¹ and JAMI investigators, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁶Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁷Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁸Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹¹Department of Rheumatology, Jichi Medical University Saitama Medical Center, Saitama, Japan, ¹²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan
Background/Purpose: Environmental triggers such as infection are considered to be involved in pathogenesis of polymyositis (PM) and dermatomyositis (DM). This study was aimed to investigate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].